記事
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
Digital data available（Crossref）
Begin reading now
CiNii Research
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
- Material type
- 記事
- Author
- Norihiro Kokudoほか
- Publisher
- Wiley
- Publication date
- 2019-09-06
- Material Format
- Digital
- Journal name
- Hepatology Research 49 10
- Publication Page
- p.1109-1113
Detailed bibliographic record
Summary, etc.：
- <jats:p>The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to t...
Holdings of Libraries in Japan
This page shows libraries in Japan other than the National Diet Library that hold the material.
Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.
other
CiNii Research
Search ServiceDigitalYou can check the holdings of institutions and databases with which CiNii Research is linked at the site of CiNii Research.
Bibliographic Record
You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.
Digital
- Material Type
- 記事
- Author Heading
- Publication Date
- 2019-09-06
- Publication Date (W3CDTF)
- 2019-09-06
- Periodical title
- Hepatology Research
- No. or year of volume/issue
- 49 10
- Volume
- 49
- Issue
- 10
- Pages
- 1109-1113
- Publication date of volume/issue (W3CDTF)
- 2019-09-06
- ISSN (Periodical Title)
- 13866346
- Publication (Periodical Title)
- Wiley
- Subject Heading
- Target Audience
- 一般
- DOI
- 10.1111/hepr.13411
- Date Created (W3CDTF)
- 2019-07-23
- Rights (production)
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- Related Material (URI)
- Is Referenced By
- Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humansPathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal TrunkEarly Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization<i>IL‐28B</i> variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapyClinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatmentMulticenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH studyConsensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imagingZinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathyEffect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and AblationIndications of Laparoscopic Repeat Liver Resection for Recurrent Hepatocellular CarcinomaEffect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysisEffectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target LesionsSafety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysisArtificial intelligence models for the diagnosis and management of liver diseasesRisk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis BControlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort StudyST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular CarcinomaModified albumin–bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patientsLiver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosisEarly experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practicePrediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk ModelsAdaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosisIncreasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year studyPerioperative Geriatric Assessment as A Predictor of Long-Term Hepatectomy Outcomes in Elderly Patients with Hepatocellular CarcinomaHigher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic LiversElevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cellsReevaluation of Makuuchi’s criteria for resecting hepatocellular carcinoma: A Japanese nationwide surveyCurrent status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL)Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinomaSurvival benefit of <scp>l</scp>‐carnitine supplementation in patients with cirrhosisRisk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosisImmune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer CellsEffectiveness of CT‐image guidance in proton therapy for liver cancer and the importance of daily dose monitoring for tumors and organs at riskAssociation between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C eliminationLate Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with CirrhosisEffect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with LenvatinibPrediction of the prognosis of advanced hepatocellular carcinoma by <i>TERT</i> promoter mutations in circulating tumor DNAImpact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with LenvatinibThe Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven CriteriaMyostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinomaPrediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or SmallerRisk factors for liver‐related mortality of patients with hepatitis C virus after sustained virologic response to direct‐acting antiviral agentsComparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative TreatmentDynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impactsImpact of skeletal muscle volume on patients with <scp>BCLC stage‐B</scp> hepatocellular carcinoma undergoing sorafenib therapyDurable complete response is achieved by balloon‐occluded transcatheter arterial chemoembolization for hepatocellular carcinomaClinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)Protein Kinase C Delta Is a Novel Biomarker for Hepatocellular CarcinomaValidity of the Algorithm for Liver Resection of Hepatocellular Carcinoma in the Caudate LobeTumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinomaGlasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysisEffect of albumin measurement methods on the albumin–bilirubin gradeBaseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinomaClinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular CarcinomaSerum alpha-fetoprotein increases prior to fibrosis resolution in a patient with acute liver failureCombination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing <scp>nonsurgical</scp> hepatocellular carcinoma therapyComparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® SystemsAcquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsLong‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antiviralsPrediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct‐acting anti‐viralsSerum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationFucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosisClinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspectiveEffect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapyA simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosisAnalyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective studyRecurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case reportA Case of Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus TremelimumabMedical Treatment for Hepatocellular Carcinoma in JapanOutcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center StudyAdvanced chronic liver diseaseにおけるMRエラストグラフィの役割についてImproving the sensitivity of liver tumor classification in ultrasound images <i>via</i> a power-law shot noise modelPreoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical TrialSimple Stratification of Hepatocellular Carcinoma Surveillance after Direct-acting Antiviral Therapy for Chronic Hepatitis CCOVID-19のアウトブレイク時における肝細胞がん治療のガイダンスEarly hemodynamics of hepatocellular carcinoma using contrast-enhanced ultrasound with Sonazoid: focus on the pure arterial and early portal phasesSelection of patients with esophageal varices for liver resection of hepatocellular carcinomaCurrent Status of Hepatocellular Carcinoma Occurrence after Achieving a Sustained Virologic Response with Direct-Acting Antiviral Drug Treatment for Type C Chronic Liver Disease: A Study at Kawasaki Municipal Tama HospitalConversion therapy and maintenance therapy for primary hepatocellular carcinomaMRI（magnetic resonance imaging）による肝疾患サルコペニアの診断と病態分析Subcutaneous Fat Thickness of the Lower Limb is Associated with Trunk Muscle Mass in Patients with Hepatocellular Carcinoma: A Simple Assessment for Sarcopenia Using Conventional UltrasonographyThe clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 updateAntitumor Effect of Zinc Acetate in Hepatocellular Carcinoma Cell Lines via the Induction of ApoptosisWhat liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics
- References
- Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinomaClinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from JapanPhase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).Evidence‐based <scp>C</scp>linical <scp>P</scp>ractice <scp>G</scp>uidelines for <scp>H</scp>epatocellular <scp>C</scp>arcinoma: The <scp>J</scp>apan <scp>S</scp>ociety of <scp>H</scp>epatology 2013 update (3rd <scp>JSH‐HCC G</scp>uidelines)A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular CarcinomaDevelopment of evidence‐based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in JapanArterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialSorafenib in Advanced Hepatocellular CarcinomaA Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan CriteriaRandomized clinical trial of chemoembolization plus radiofrequency ablation <i>versus</i> partial hepatectomy for hepatocellular carcinoma within the Milan criteriaSurvival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasionComparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide surveyA randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinomaEfficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialManagement of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of HepatologyGRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tablesClinical practice guidelines for hepatocellular carcinoma-the Japan Society of Hepatology 2009 update
- Data Provider (Database)
- 国立情報学研究所 : CiNii Research
- Original Data Provider (Database)
- Crossref科学研究費助成事業データベース科学研究費助成事業データベース科学研究費助成事業データベース科学研究費助成事業データベースCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossrefCrossref